[go: up one dir, main page]

WO2003066075A1 - Produit de traitement de la dysbacteriose et procede de fabrication correspondant - Google Patents

Produit de traitement de la dysbacteriose et procede de fabrication correspondant Download PDF

Info

Publication number
WO2003066075A1
WO2003066075A1 PCT/RU2003/000040 RU0300040W WO03066075A1 WO 2003066075 A1 WO2003066075 A1 WO 2003066075A1 RU 0300040 W RU0300040 W RU 0300040W WO 03066075 A1 WO03066075 A1 WO 03066075A1
Authority
WO
WIPO (PCT)
Prior art keywords
normal
microorganism
disease
human intestine
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2003/000040
Other languages
English (en)
Russian (ru)
Inventor
Konstantin Georgievich Gourevitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003235527A priority Critical patent/AU2003235527A1/en
Publication of WO2003066075A1 publication Critical patent/WO2003066075A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the invention is related to biotechnology, and specifically to biological active drugs for medicine and veterinary medicine, which normalizes the gastric-intestinal tract
  • P ⁇ d disba ⁇ e ⁇ i ⁇ z ⁇ m ⁇ ni mayu ⁇ change ⁇ aches ⁇ venn ⁇ g ⁇ and ⁇ liches ⁇ venn ⁇ g ⁇ s ⁇ s ⁇ ava ba ⁇ e ⁇ ialn ⁇ y ⁇ l ⁇ y, ⁇ busl ⁇ vlenn ⁇ e dinamiches ⁇ im na ⁇ usheniem mi ⁇ e ⁇ l ⁇ gii ⁇ ishechni ⁇ a in ⁇ ezul ⁇ a ⁇ e s ⁇ yva ada ⁇ atsii, na ⁇ usheniya zaschi ⁇ ny ⁇ and ⁇ m ⁇ ensa ⁇ ny ⁇ me ⁇ anizm ⁇ v ⁇ ganizma.
  • dysbacteriosis The main reasons for the development of dysbacteriosis are:
  • ⁇ azmn ⁇ zhenie usl ⁇ vn ⁇ ⁇ a ⁇ genny ⁇ mi ⁇ ganizm ⁇ v ⁇ iv ⁇ di ⁇ ⁇ v ⁇ zni ⁇ n ⁇ veniyu ⁇ unis ⁇ iches ⁇ i ⁇ in ⁇ e ⁇ tsy, u ⁇ udsheniyu ⁇ echeniya ⁇ sn ⁇ vn ⁇ g ⁇ zab ⁇ levaniya and ⁇ a ⁇ zhe ⁇ azvi ⁇ iyu ⁇ azlichny ⁇ na ⁇ usheny s ⁇ s ⁇ ny zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ g ⁇ ⁇ a ⁇ a (dia ⁇ eya, and ⁇ li ⁇ y ⁇ . ⁇ .).
  • Vitamin therapy as a means, aimed at increasing the resistance of the body, and as a substitute for therapy, ⁇ . ⁇ . the synthesis of vitamins and dysbacterioses is disturbed by: thiamine, riboflavin, pyridoxine, vitamin ⁇ , ascorbic acid and nitrous acid (Grebnev L. L., chili peppermina;
  • the drug was known to be a suspension of live bacteria of strain ⁇ . ⁇ .
  • the product is characterized by pronounced antagonism in relation to 8/11, which is inactive., 5
  • the drug is known to be bifidumbacterin, which is a proprietary freeze-dried mixture of biofoods
  • v ⁇ zm ⁇ zhn ⁇ s ⁇ i ⁇ dli ⁇ eln ⁇ g ⁇ (at least ⁇ dn ⁇ g ⁇ g ⁇ da) ⁇ aneniya and ⁇ vyshayu ⁇ i ⁇ an ⁇ ag ⁇ nis ⁇ iches ⁇ uyu a ⁇ ivn ⁇ s ⁇ in ⁇ n ⁇ shenii ⁇ a ⁇ genny ⁇ and usl ⁇ vn ⁇ ⁇ a ⁇ genny ⁇ mi ⁇ ganizm ⁇ v - v ⁇ zbudi ⁇ eley ⁇ ishechny ⁇ in ⁇ e ⁇ tsy and dia ⁇ eyny ⁇ s ⁇ s ⁇ yany and ⁇ a ⁇ zhe s ⁇ s ⁇ bs ⁇ vuyu ⁇ immuni ⁇ e ⁇ a ⁇ ganizma strengthening and improving ⁇ bschemu me ⁇ ab ⁇ lizma.
  • the biologically active state of microbial cells is in suspension, in the case of free-form cells, where the bacteria are alive, but in the state of anabiosis. This ensures the immediate effect of the drugs, starting with the outside of the food processing department, which is the cause of the overwhelming disease.
  • the mechanism of suppression and displacement of enteric agents includes: allocation of antagonistic substances, competition for the disposal of household substances, competition for adhesives. In the presence of plant extracts, resulting from a special technology.
  • Hormonal organisms of the human intestinal tract used by the claimed invention may include: ⁇ a ⁇ imer ⁇ , ⁇ . ⁇ ⁇ 17, b. ⁇ se ⁇ Shiz, b. herebyegte ⁇ sht, ⁇ Consequently Consequently ⁇ sht, ⁇ Consequently Consequently ⁇ sht, ⁇ Consequently Consequently ⁇ Consequently Consequently ⁇ sht, ⁇ Consequently Consequently Consequently ⁇ Consequently ⁇ sht, ⁇ Consequently Consequently ⁇ Consequently Consequently ⁇ sht, ⁇ Consequently Consequently . . 8
  • one of the methods of cultivation is introduced, for example, ⁇ . SOI ⁇ 17, which does not limit the scope of the claimed invention.
  • the resulting mixture was then centrifuged.
  • a convenient biomass could be stored in a refrigerator for 48 hours with the storage of all properties.
  • Raw materials used in the manufacture of Kazakh-based foods can be any plant matter, preferably selected from soy, beetroot, garlic, cooked meat, meat
  • the invention affects the process of the preparation of the product, consisting of, at the very least, one of the output of the process from the production of raw materials, the supply of
  • EXAMPLE 2 Methods of production of plant extracts. Fresh vegetables (8-10 kg), washed in the fresh water, and grind to the formation of biomass. Mix with liquid ⁇ 0 2 at a ratio of 1: 10. Drain the hi-siting liquid and place it in the evaporator under reduced pressure (5-10 mm), because the temperature is not too high. After removal of the volatile fraction ( ⁇ 0 2 ), the finished extract will remain in the evaporator. This material may be stored under refrigeration for up to 1 year, with all its properties preserved. Each product (various domestic plants) is prepared separately, and then mixed up if necessary.
  • P ⁇ sle ⁇ g ⁇ , ⁇ a ⁇ were ⁇ lucheny ⁇ as ⁇ i ⁇ elnye e ⁇ s ⁇ a ⁇ y, ⁇ ⁇ ayney me ⁇ e, ⁇ din of ni ⁇ sus ⁇ endi ⁇ uyu ⁇ with e ⁇ e ⁇ ivnym ⁇ liches ⁇ v ⁇ m, ⁇ ⁇ ayney me ⁇ e, ⁇ dn ⁇ g ⁇ form ⁇ bi ⁇ iches ⁇ g ⁇ mi ⁇ ganizma, a ⁇ ivn ⁇ g ⁇ in zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ m ⁇ a ⁇ e chel ⁇ ve ⁇ a ( ⁇ ishechnaya ⁇ al ⁇ ch ⁇ a, la ⁇ ba ⁇ e ⁇ ii, bi ⁇ id ⁇ ba ⁇ e ⁇ ii, veyl ⁇ nelly, en ⁇ e ⁇ i and d ⁇ ., preferably, ⁇ . ⁇ o ⁇ ⁇ 17).
  • the final concentration of the industrial organization which is the normal size of the human population, is less than 100 million.
  • the scope of the claimed invention is preferable to use a mixture of plant extracts.
  • One of the incidents of such a combination may be a mixture of extracts of alfalfa, soybeans, beets, spices, taken at a ratio of 2: 8: 4: 1, or a mixture of emancipations, / 5: 1.
  • Composition 2 is a composition of Composition 2:
  • Composition 3 is a composition of Composition 3:
  • Spike cages live ⁇ . ⁇ ⁇ 17 not less than 100 million cells
  • Composition 5 is a composition of Composition 5:
  • the product may also be optionally enriched with other essential macronutrients and microelements.
  • the first two groups - patients with gastric ulcer and duodenal ulcers in the stage of the disease, they differed only in large-scale anti-inflammatory disease.
  • the group made up patients with pneumonia, who received a combination of antibiotics.
  • ⁇ 4 groups included patients with gynecological departments with treatment for chronic salpingitis, endometritis and other diseases that were treated.
  • the fifth group was made up of patients with irritable bowel syndrome (chronic diarrhea) who did not receive antibiotic therapy.
  • the average daily average is 37.8 years.
  • Example 5 The clinical effect of S8-S ⁇ G in an oncologic patient.
  • ⁇ liniches ⁇ ie is ⁇ y ⁇ aniya ⁇ az ⁇ g ⁇ -S ⁇ t ⁇ g ⁇ were ⁇ vedeny 237 b ⁇ lny ⁇ ⁇ a ⁇ m ⁇ vi, zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ g ⁇ ⁇ a ⁇ a, ma ⁇ i, m ⁇ l ⁇ chn ⁇ y gland and yaichni ⁇ v, ⁇ divshi ⁇ s ⁇ anda ⁇ nye ⁇ u ⁇ sy ⁇ imi ⁇ e ⁇ a ⁇ ii - ⁇ azdeln ⁇ or s ⁇ che ⁇ anii with luchev ⁇ y ⁇ e ⁇ a ⁇ iey.
  • Patients were received on an entire course of treatment (depending on nosology - from 3 to 10 weeks). The out of 115 sick group did not receive any treatment.
  • the drug can be used in the veterinary medicine for the treatment and treatment of home-made acne and medicine.
  • Bacterial resistance to the antibiotics used as growth enhancers and therapies in home equity causes strong debts in the benefit of the future. Ineffective patient strains may be hindered by unfair or inadequate livelihoods. Otherwise, the separating factors of the resistances can be transfered with of the transgenic bacteria resistant to the susceptible. 18
  • the observed parameters were: mobility, exposure and severity of diarrhea, administration, food intake and weight gain.
  • the usual causes of diarrhea are: founded.
  • Kazahgo-Sostogo is added to potable water in an amount of 0.01 ml per day for pulp during the course of the dilution (42-49 days). Convenient tests on boilers showed a 3.2% increase in weight gain and a 4% improvement in digestion. 20
  • Iz ⁇ b ⁇ e ⁇ enie ⁇ myshlenn ⁇ ⁇ imenim ⁇ and naib ⁇ lee us ⁇ eshn ⁇ m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ in bi ⁇ e ⁇ n ⁇ l ⁇ gii and imenn ⁇ ⁇ a ⁇ bi ⁇ l ⁇ giches ⁇ i a ⁇ ivny ⁇ e ⁇ a ⁇ a ⁇ for medicine and ve ⁇ e ⁇ ina ⁇ ii, n ⁇ malizuyuschy mi ⁇ l ⁇ u zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ g ⁇ ⁇ a ⁇ a and ingibi ⁇ uyuschy ⁇ azvi ⁇ ie ⁇ a ⁇ genny ⁇ mi ⁇ ganizm ⁇ v.
  • the receipt of the product in accordance with the present invention may be carried out on any well-known equipment with the help of known products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention relève du domaine des biotechnologies et notamment des préparations bioactives pour la médecine, qui servent à normaliser la microflore du tractus intestinal et à freiner le développement des micro-organismes pathogènes. L'invention concerne un procédé de fabrication et une préparation pour traiter la disbactériose, qui contient une quantité efficace d'au moins un type de micro-organisme probiotique constituant la flore intestinale normale de l'humain ainsi qu'au moins un extrait d'un légume. L'invention permet d'augmenter l'efficacité du traitement grâce à son action immédiate.
PCT/RU2003/000040 2002-02-08 2003-02-07 Produit de traitement de la dysbacteriose et procede de fabrication correspondant Ceased WO2003066075A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003235527A AU2003235527A1 (en) 2002-02-08 2003-02-07 Medication for curing dysbacteriosis and the method for production thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2002103062 2002-02-08
RU2002103062/15A RU2221582C2 (ru) 2002-02-08 2002-02-08 Средство для лечения дисбактериоза и способ его получения

Publications (1)

Publication Number Publication Date
WO2003066075A1 true WO2003066075A1 (fr) 2003-08-14

Family

ID=27731047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2003/000040 Ceased WO2003066075A1 (fr) 2002-02-08 2003-02-07 Produit de traitement de la dysbacteriose et procede de fabrication correspondant

Country Status (3)

Country Link
AU (1) AU2003235527A1 (fr)
RU (1) RU2221582C2 (fr)
WO (1) WO2003066075A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2267325C2 (ru) * 2004-02-27 2006-01-10 Роберт Мейнгардтович Линд Препарат для снижения белкового дефицита в организме и способ получения такого препарата
RU2322252C1 (ru) * 2006-12-05 2008-04-20 Игорь Юрьевич Давыдкин Иммунобиологическое средство, обладающее способностью стимулировать психоэмоциональную адаптацию человека (варианты) и штамм bifidobacterium bifidum 1c
RU2332226C1 (ru) * 2007-06-09 2008-08-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Сбор лекарственных растений для профилактики и комплексного лечения дисбактериоза кишечника

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756913A (en) * 1985-09-30 1988-07-12 Khorkova Evgenia A Sour milk product
RU2110927C1 (ru) * 1997-05-21 1998-05-20 Ян Маатасимович Аль-Нури Биопрепарат "анта-1"-кормовая добавка для бройлерных цыплят
RU2144954C1 (ru) * 1998-04-15 2000-01-27 Лившиц Виталий Аркадьевич ШТАММ БАКТЕРИЙ Escherichia coli M 17/p Colap, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ ПРОБИОТИЧЕСКОГО ПРЕПАРАТА

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756913A (en) * 1985-09-30 1988-07-12 Khorkova Evgenia A Sour milk product
RU2110927C1 (ru) * 1997-05-21 1998-05-20 Ян Маатасимович Аль-Нури Биопрепарат "анта-1"-кормовая добавка для бройлерных цыплят
RU2144954C1 (ru) * 1998-04-15 2000-01-27 Лившиц Виталий Аркадьевич ШТАММ БАКТЕРИЙ Escherichia coli M 17/p Colap, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ ПРОБИОТИЧЕСКОГО ПРЕПАРАТА

Also Published As

Publication number Publication date
AU2003235527A1 (en) 2003-09-02
RU2221582C2 (ru) 2004-01-20

Similar Documents

Publication Publication Date Title
Campbell-McBride Gut and psychology syndrome: Natural treatment for autism, dyspraxia, ADD, dyslexia, ADHD, depression, schizophrenia
KR100694820B1 (ko) 박테리아 균주 및 인간 및 수의학적 사용을 위한 생균활성 조성물
Lauzon et al. Probiotics and prebiotics: concepts, definitions and history
CN106413724B (zh) 与多糖聚合物粘合剂缀合的鼠李糖乳杆菌rht-3201及其用途
CN108968058A (zh) 一种调理肠道的益生菌酵素组合物及应用
WO1997037672A1 (fr) Preparation biosynthetique poudreuse se composant de bois de rennes ossifies, et additif alimentaire a base de cette preparation biosynthetique
KR101133208B1 (ko) 식물성 유산균을 이용한 장개선과 변비개선효과를 나타내는 기능성 대두 발효조성물 제조방법
CA2316671A1 (fr) Produits fonctionnels et methode de traitement et de prevention du cancer et d'autres affections degeneratives
Tarasiuk et al. Nutritional support and probiotics as a potential treatment of IBD
CN111067109A (zh) 一种膳食纤维组合物及其制备方法与应用
CN107647410A (zh) 一种复合配比的益生菌粉及其制备方法
US11278578B2 (en) Combination probiotic compositions and uses thereof
WO2003066075A1 (fr) Produit de traitement de la dysbacteriose et procede de fabrication correspondant
CN110169984B (zh) 一种发菜藻粉在调节肠道菌群结构中的应用
KR102000170B1 (ko) 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품
Campbell-McBride Gut and psychology syndrome
CN109700031A (zh) 用于肠道清洁、肠道排毒的营养组合物
RU2322995C1 (ru) Биопрепарат ветеринарного назначения и способ профилактики желудочно-кишечных болезней новорожденных телят с его применением
KR102609638B1 (ko) 미역귀 추출물을 유효성분으로 포함하는 장내 균총 개선용 조성물
CN118251136A (zh) 生理学上可接受的酵母菌组合物及其用途
CN106819223A (zh) 一种保健奶茶及其制备方法
Kiers Effects of fermented soya bean on digestion, absorption and diarrhoea
Ghannoum Total Gut Balance: Fix Your Mycobiome Fast for Complete Digestive Wellness
Gupta et al. Agri-Nutri Strategies to Overcome Malnutrition
CN104222272A (zh) 浒苔益生菌饮料

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP